123549-15-5

Basic information

• Product Name: oroxylin A 7-acetyl ester
• Synonyms: oroxylin A 7-acetyl ester
• CAS NO: 123549-15-5
• Molecular Weight: 326.306
• Mol File: 123549-15-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: oroxylin A 7-acetyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: oroxylin A 7-acetyl ester(123549-15-5)
• EPA Substance Registry System: oroxylin A 7-acetyl ester(123549-15-5)

Safety Data

• Hazardous Substances Data: 123549-15-5(Hazardous Substances Data)

Upstream product

• 82475-03-4 Baicalin methyl ester 
• 480-11-5 oroxylin A 
• 75-36-5 acetyl chloride 
• 21967-41-9 baicalin 
• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 

Relevant articles and documents

Synthesis and in vitro study of novel 7-O-acyl derivatives of Oroxylin a as antibacterial agents

A series of Oroxylin A derivatives, prepared by alkylation and condensation, were fully characterized by spectroscopic methods. All the derivatives were screened for antibacterial activity against a panel of susceptible and resistant Gram-positive and Gram-negative organisms. It was observed that acylation of 7-OH group in Oroxylin A significantly enhanced the activity as compared to their parent compound (Oroxylin A).

Application of oroxylin A and pro-drug thereof as catechol-type medicine synergist

An application of oroxylin A and a pro-drug thereof as a catechol-type medicine synergist belongs to the technical field of medicines. The compound is used as the catechol-type medicine synergist and has the following structure general formula (I), wherein R is hydrogen, carboxylic ester, glucuronic acid and the like substitutive groups. One or more compounds of the oroxylin A and the pro-drug thereof can be mixed with levodopa according to a certain ratio to prepare a drug composition for treatment of Parkinson's disease. The oroxylin A and the pro-drug prepared through modification thereof are improved in both solubility and transmembrane capability and are significantly prolonged in in-vivo metabolic half life period, which is longer than the in-vivo metabolic half life periods of majority of catechol-type medicines, so that the compounds have excellent medicine preparation prospect. In addition, the compounds also can be combined with a catechol-type medicine to form a compound medicine. The compound medicine can be prepared into an oral-taking slow-release preparation to further improve oral-taking bioavailability and treatment effects of the catechol-type medicines.